Indivumed Launches the nRavel™ AI Platform for Cancer Research and Drug Development
HAMBURG, Germany, June 2, 2021 /PRNewswire/ --Indivumed GmbH ("Indivumed") today announced the launch of nRavelTM, a unique AI discovery platform for oncology and precision medicine.
- HAMBURG, Germany, June 2, 2021 /PRNewswire/ --Indivumed GmbH ("Indivumed") today announced the launch of nRavelTM, a unique AI discovery platform for oncology and precision medicine.
- Most recently, Merck KGaA, Darmstadt, Germany signed a master collaboration agreement with Indivumed to utilize nRavel's capabilities for the company's drug development activities.
- "The nRavelTM platform puts Indivumed ahead of all other AI-driven drug development platforms.
- "We look forward to partnering with Merck KGaA, Darmstadt, Germany, who recognized our nRavelTM platform as an exciting new solution for drug development."